PDS Biotechnology (PDSB) announced details of a sub-analysis of the cohort of patients with low PD-L1 expression, or CPS 1-19, from the final data ...

Bacteria have long been a key source of lifesaving antibiotics, but most species cannot be grown in the lab—leaving their ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...

Oncolytics Biotech ( ($ONCY) ) just unveiled an update. Oncolytics Biotech announced updates on the GOBLET trial, which evaluates pelareorep in ...

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and ...

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

Shares of aTyr Pharma collapsed Monday after the clinical-stage biotechnology company's most advanced program failed in a late-stage study. ATyr shares were recently changing hands at $1.14, down 81% ...